# NCT05410145 (NCT05410145)

> A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05410145
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: D3 Bio (Wuxi) Co., Ltd
- Conditions: KRAS P.G12C
- Interventions: D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab
- Enrollment: 442
- Primary outcome: Number of Participants With Adverse Events (AEs)
- Primary outcome: Number of Participants With Dose-Limiting Toxicities (DLTs)

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05410145